[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603038":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":21,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":21,"studyType":69,"phases":70,"briefSummary":73,"conditions":74,"keywords":21,"overallStatus":40,"whyStopped":21,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Second Affiliated Hospital of Nanchang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SFRT concurrent with tislelizumab and platinum - based doublet chemotherapy","EXPERIMENTAL","SFRT concurrent with immunochemotherapy is given q3w for 3 cycles. Here are details:\n\nRadiotherapy: Select several 1 - cm - diameter spherical areas in the primary tumor's hypoxic region, 1.5 - 2 cm apart. Each area receives a single 12 - Gy high - dose radiotherapy, precisely targeting the hypoxic part to enhance the effect.\n\nChemotherapy \\& Immunotherapy: 1 - 3 days after radiotherapy, combine 200 mg of tislelizumab with platinum - based doublet chemotherapy. NSCLC chemo - drug combos vary by pathology. For adenocarcinoma, use pemetrexed (500 mg\u002Fm² d1) + carboplatin (AUC 5, d1). For other types, use albumin - bound paclitaxel (100 mg\u002Fm² d1,8) + carboplatin (AUC 5, d1).",[13,14,15],"Other: Spatially Fractionated Radiotherapy (SFRT)","Drug: Tislelizumab, Carboplatin, Pemetrexed","Drug: Tislelizumab, paclitaxel, Carboplatin",[17,22,27],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"Spatially Fractionated Radiotherapy (SFRT)","Several spherical volumes (with a diameter of 1 cm) are selected within the hypoxic area of the primary tumor. The distance between each spherical volume is 1.5 - 2 cm, and a high-dose radiotherapy of 12 Gy × 1F is delivered.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","Tislelizumab, Carboplatin, Pemetrexed","For adenocarcinoma, pemetrexed (500 mg\u002Fm², day 1) + carboplatin (AUC 5, day 1) is used.",[9],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":21},"Tislelizumab, paclitaxel, Carboplatin","For NSCLC with pathological types other than adenocarcinoma, nab-paclitaxel (100 mg\u002Fm² on day 1 and day 8) + carboplatin (AUC 5, day 1) is used.",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},"jing cai Jing Cai","CONTACT","15270905381","cjdl879@163.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Nanchang City, Jiangxi Province","RECRUITING","Nanchang","Jiangxi","330000","China","CN",{"type":47,"coordinates":48},"Point",[49,50],115.85306,28.68396,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":35,"phoneExt":21,"email":36},{"type":55,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100603038","phase-2-sfrttislelizumabplatinum-chemotherapy-for-unresectable-stage-iii-nsclc-100603038",false,"NCT07131319","SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","Spatially Fractionated Radiotherapy (SFRT) Synchronized With Tislelizumab Plus Platinum-based Dual-agent Chemotherapy for Induction Treatment of Initially Unresectable Stage Ⅲ Non-small Cell Lung Cancer: A Clinical Study","Inclusion Criteria:\n\n* The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC).\n\nExclusion Criteria:\n\n* Has participated in another clinical study using research products within the past 3 weeks.","ALL","18 Years","85 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71,72],"PHASE2","PHASE3","The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are:\n\nWill spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?",[75],"Non-Small Cell Lung Cancer","2026-06-24",{"date":78,"type":79},"2026-06-25","ACTUAL",{"date":81,"type":79},"2025-04-21",{"date":83,"type":68},"2028-12-31",{"name":5,"class":6},1]